Ametris - formerly ActiGraph

11/14/2025

We’re proud to share that Christine Guo, Chief Scientific Officer at Ametris, was featured in the International Clinical Trials’ Women in Pharma Supplement 2025 from Samedan Inc. In this Q&A-style article, Dr. Guo shares her perspectives and first-hand experience on the impact of digital health technology (DHT) on clinical development and how the industry can embrace innovation while safeguarding scientific rigor.

You can read the full interview, as well as other stories of inspiring women in pharma, here: https://hubs.la/Q03TkS170

Welcome to the third issue of the Women in Pharma Supplement 2025. Check out all the newest insights from our wide selection of female leaders in the pharma industry.

11/13/2025

We’re excited to announce a new member of the Accelerant Partnership Program, Lingyan Innovation!

🤝 This strategic partnership brings together expertise to deploy wearable digital health technology to support decentralized clinical trials and patient-centric drug development in China, one of the fastest-growing research environments in the world.

Read more here: https://hubs.la/Q03T5rR20

Ametris partners with Lingyan Innovation to support decentralized clinical trials and advance the digitization of clinical research in China.

11/13/2025

📣 Join us next week for the November session of our Digital Health Monthly webinar series: AI, Sensors, and Regulation: What We Learned at ADDS Basel and Why It Matters.

Artificial intelligence, advanced sensors, and evolving regulatory frameworks are redefining what’s possible in digital health research. Join us on Nov. 19 to discover firsthand insights from ADDS Basel 2025, the inaugural European edition of our flagship scientific meeting, as Ametris Science Team members Christine Guo, Sylvain Zorman, and Michael Pettinati discuss key takeaways and their impact on the future of clinical evidence generation and regulatory pathways.

You’ll learn how clinical research teams are:
🔹 Applying AI and machine learning to continuous digital data
🔹 Expanding use of sensor-derived measures across key therapeutic areas
🔹 Advancing regulatory readiness for DHT-derived endpoints

Attendees will also get a sneak peek into the ADDS 2026 annual meeting, Feb 23-25 in Atlanta, GA. Don’t miss this opportunity to stay at the forefront of DHT innovation!

👇 Registration link in comments below.

11/11/2025

📣 This is the LAST CALL to submit your abstract to the Scientific Poster Session at ADDS 2026!

We invite you to submit your abstract for consideration to be included in the poster session no later than Sunday, Nov. 16, 2025.

✔️ Research must include wearable digital health technology
✔️ Abstracts must contain original, unpublished data

New this year - short talk opportunity! Authors of selected abstracts will have the option to present a short oral presentation in addition to/instead of a poster presentation.

👇Link to more details and submission form in the comments below.

11/07/2025

Participant adherence is one of the most critical and challenging factors influencing data quality and study success in clinical research. In a recent session of our Digital Health Monthly webinar series, DHT leaders and experts from Pfizer, J&J Innovative Medicine, Novartis, and Ametris shared their real-world perspectives on effectively managing digital health technology (DHT) adherence across the clinical trial lifecycle, including:

✔️ The importance of a comprehensive DHT-adherence strategy
✔️ Practical lessons and proven approaches from leading organizations
✔️ Adherence strategies from study planning through statistical analysis
✔️ New advances from Ametris supporting data completeness for sponsors

Our featured panel:
🔹Carrie Northcott, Head of Digital Medicine & Translational Imaging, Pfizer
🔹Mark Morris, Director Digital Clinical Medicine, J&J Innovative Medicine
🔹Lorcan Walsh, PhD, Head of Digital Endpoint Capability Centre, Novartis
🔹Robin Harris, Vice President of Client Services, Ametris
🔹Moderator: Sylvain Zorman, PhD, Director DHT Solutions Strategy, Ametris

🔗 Watch the on-demand webinar: https://hubs.la/Q03ScN8B0

11/06/2025

Artificial Intelligence (AI) is redefining the development, validation, and application of digital measures across clinical research. Powerful AI techniques applied to large datasets reveal valuable insights into disease progression, treatment response, and patient behavior that were previously unknown.

At ADDS 2026, we’ll spotlight the innovation driving this evolution with a dedicated AI Session. DHT experts and data scientists from industry and academia will explore how advanced AI frameworks and large-scale sensor data are accelerating digital endpoint development and expanding access to next-generation therapies.

Session topics include:
🌟 Shared, pre-competitive foundation models for digital endpoints
🌟 The potential of AI and digital data to expand immunotherapy access
🌟 Application of large sensor datasets to advance personal health insights

We hope you’ll join us at ADDS 2026, Feb. 23-25 in Atlanta!

👇To learn more about ADDS 2026, visit the link in the comments below.

11/03/2025

📣 Register today for the next session of our Digital Health Monthly webinar series: AI, Sensors, and Regulation: What We Learned at ADDS Basel and Why It Matters.

Artificial intelligence, advanced sensors, and evolving regulatory frameworks are redefining what’s possible in digital health research. Join us on Nov. 19 as Ametris Science Team members Christine Guo, Sylvain Zorman, and Michael Pettinati discuss key insights from ADDS Basel 2025, the first European edition of our flagship scientific meeting, and what they mean for the future of evidence generation and regulatory strategy.

You’ll learn how clinical research teams are:
🔹 Applying AI and machine learning to continuous digital data
🔹 Expanding use of sensor-derived measures across key therapeutic areas
🔹 Advancing regulatory readiness for DHT-derived endpoints

Don’t miss this opportunity to stay at the forefront of DHT innovation!

👇 Registration link in comments below.

10/31/2025

The International Society for the Measurement of Physical Behaviour (ISMPB) is holding their Virtual Fall Symposium next week, Nov 4-5! This event features expert-led presentations about developing global guidances and best practices on the use of wearable devices for monitoring physical activity. Hayden Davis, Senior Director of Public Health and Academia at Ametris, will join the discussion to share the latest updates and resources for the academic research community.

Learn more about the ISMPB Virtual Fall Symposium: https://hubs.la/Q03R5Qx_0

10/30/2025

🔊The agenda for the Ametris Digital Data Summit (ADDS) 2026 annual meeting is now available!

This one-of-a-kind scientific conference focuses on the practical use of wearable digital health technologies (DHTs) in clinical research, bringing together multidisciplinary leaders across the digital health ecosystem to explore the latest research, case studies, and innovations driving the adoption of sensor-based measures in clinical research and development.

Featured session areas include:
🔹Physical Activity and Mobility
🔹Sleep and Scratch
🔹Artificial Intelligence
🔹Regulatory
🔹Methodology
🔹Pharma Innovation

‼️Early bird registration ends this Friday, Oct 31, so register today to save up to 45% off standard rates.

👇View agenda and registration links in the comment below.

10/28/2025

At the Ametris Digital Data Summit (ADDS) 2025, we introduced a new element to our annual meeting: the ALS Workshop. This focused meeting brought together global experts across academia, industry, and patient advocacy to chart a path toward greater adoption of digital measures in ALS clinical trials.

In a new blog post, Rakesh Pilkar shares key outcomes from the ALS Workshop that he recently had the opportunity to present as a poster at NEALS 2025 in Clearwater, FL.

Highlights include:
🔹Results from a patient survey showing strong willingness to use wearable devices to help reduces clinic visits
🔹Evidence generation and regulatory readiness requirements for digital endpoints
🔹Opportunities for multi-stakeholder collaboration to progress digital measures in ALS trials

These insights reflect the momentum building within the ALS research community and the critical importance of working together to move from validation to implementation.

Read the full blog using the link in the comments 👇

10/27/2025

We’re excited to share that Sylvain Zorman, Scientific Director, DHT Solution Strategy at Ametris, will be attending Obesity Week 2025 Nov 4-7 in Atlanta!

Our team is passionate about advancing the understanding of obesity and metabolic disorders through continuous, real-world data from digital health technologies. If you’re interested in discussing how novel digital endpoints can support your next clinical program or want to learn more about our new DECODE Obesity working group, we’d love to connect.

📅 Schedule a meeting using the link in the comments.

10/21/2025

📣 Please join us on Nov 19 for the next session of Digital Health Monthly - AI, Sensors, and Regulation: What We Learned at ADDS Basel and Why It Matters.

Artificial intelligence, advanced sensors, and evolving regulatory frameworks are redefining what’s possible in digital health research. Join Ametris Science Team members Christine Guo, Sylvain Zorman, and Michael Pettinati for a discussion on key insights from ADDS Basel 2025, the first European edition of our flagship scientific meeting, and what they mean for the future of evidence generation and regulatory strategy.

You’ll learn how clinical research teams are:
🔹 Applying AI and machine learning to continuous digital data
🔹 Expanding use of sensor-derived measures across key therapeutic areas
🔹 Advancing regulatory readiness for DHT-derived endpoints

Don’t miss this opportunity to stay at the forefront of DHT innovation!

👇 Registration link in comments below.